BELEODAQ Market Drug Insight
“BELEODAQ Market Size, Forecast, and Drug Insight – 2032” report provides comprehensive insights about BELEODAQ for Peripheral T-cell lymphoma (PTCL) in the United States. A detailed picture of the BELEODAQ for Peripheral T-cell lymphoma (PTCL) in the United States for the study period 2019–2032 is provided in this report along with a detailed description of the BELEODAQ for Peripheral T-cell lymphoma. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the BELEODAQ market forecast, analysis for Peripheral T-cell lymphoma in the United States, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Peripheral T-cell lymphoma.
Drug Summary
BELEODAQ (belinostat), an HDAC inhibitor, has been assessed in several clinical trials as a sole treatment (monotherapy) or combined with other anti-cancer treatments for hematological cancers and solid tumors. Its anti-cancer activity is associated with the inhibition of cell proliferation, the induction of apoptosis (programmed cell death), the inhibition of angiogenesis, and the induction of cellular differentiation.
BELEODAQ is indicated for treating adult patients with relapsed or refractory PTCL. This indication is approved based on tumor response rate and DoR.
In April 2017, Onxeo, in collaboration with Clinigen Group, launched a Managed Access program for belinostat (marketed as BELEODAQ in the US) in Europe. The program was expected to allow physicians to request belinostat for specific patients for whom alternative treatment options are not currently available. On a named patient basis, this would have allowed access to belinostat ahead of a potential EU approval.
Dosage and administration
The recommended dosage of BELEODAQ is 1,000 mg/m2 administered over 30 minutes by intravenous infusion once daily on Days 1–5 of a 21-day cycle. Cycles can be repeated until disease progression or unacceptable toxicity.
Scope of the Report
The report provides insights into:
- A comprehensive product overview including the BELEODAQ description, mechanism of action, dosage and administration, research and development activities in Peripheral T-cell lymphoma (PTCL).
- Elaborated details on BELEODAQ regulatory milestones and other development activities have been provided in this report.
- The report also highlights the BELEODAQ research and development activity in Peripheral T-cell lymphoma in detail across the United States.
- The report also covers the patents information with expiry timeline around BELEODAQ.
- The report contains forecasted sales of BELEODAQ for Peripheral T-cell lymphoma till 2032.
- Comprehensive coverage of the late-stage emerging therapies for Peripheral T-cell lymphoma.
- The report also features the SWOT analysis with analyst views for BELEODAQ in Peripheral T-cell lymphoma.
Methodology
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
BELEODAQ Analytical Perspective by DelveInsight
In-depth BELEODAQ Market Assessment
This report provides a detailed market assessment of BELEODAQ in Peripheral T-cell lymphoma (PTCL) in the United States. This segment of the report provides forecasted sales data from 2023 to 2032.
BELEODAQ Clinical Assessment
The report provides the clinical trials information of BELEODAQ in Peripheral T-cell lymphoma covering trial interventions, trial conditions, trial status, start and completion dates.
Report Highlights
- In the coming years, the market scenario for Peripheral T-cell lymphoma (PTCL) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
- The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence BELEODAQ dominance.
- Other emerging products for Peripheral T-cell lymphoma are expected to give tough market competition to BELEODAQ and launch of late-stage emerging therapies in the near future will significantly impact the market.
- A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of BELEODAQ in Peripheral T-cell lymphoma.
- Our in-depth analysis of the forecasted sales data from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the BELEODAQ in Peripheral T-cell lymphoma.
Key Questions
- What is the product type, route of administration and mechanism of action of BELEODAQ?
- What is the clinical trial status of the study related to BELEODAQ in Peripheral T-cell lymphoma (PTCL) and study completion date?
- What are the key collaborations, mergers and acquisitions, licensing and other activities related to the BELEODAQ development?
- What are the key designations that have been granted to BELEODAQ for Peripheral T-cell lymphoma?
- What is the forecasted market scenario of BELEODAQ for Peripheral T-cell lymphoma?
- What are the forecasted sales of BELEODAQ in the United States?
- What are the other emerging products available in Peripheral T-cell lymphoma and how are they giving competition to BELEODAQ for Peripheral T-cell lymphoma?
- Which are the late-stage emerging therapies under development for the treatment of Peripheral T-cell lymphoma?
